Intellia Therapeutics (NASDAQ:NTLA)‘s stock had its “hold” rating reaffirmed by analysts at Oppenheimer in a research report issued to clients and investors on Monday.

NTLA has been the subject of several other reports. Credit Suisse Group increased their target price on shares of Intellia Therapeutics from $24.00 to $28.00 and gave the stock an “outperform” rating in a report on Friday, November 3rd. ValuEngine raised shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 22nd. Jefferies Group set a $42.00 target price on shares of Intellia Therapeutics and gave the stock a “buy” rating in a report on Tuesday, October 31st. Leerink Swann increased their price objective on shares of Intellia Therapeutics from $29.00 to $37.00 and gave the company an “outperform” rating in a report on Tuesday, October 31st. They noted that the move was a valuation call. Finally, Wedbush reaffirmed an “ourperform” rating and set a $25.00 price objective (down from $29.00) on shares of Intellia Therapeutics in a report on Wednesday, September 27th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $30.17.

Intellia Therapeutics (NTLA) traded up $0.98 during midday trading on Monday, hitting $18.37. 2,734,100 shares of the stock traded hands, compared to its average volume of 376,905. Intellia Therapeutics has a 12-month low of $10.83 and a 12-month high of $33.34.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Tuesday, October 31st. The company reported ($0.44) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.06. Intellia Therapeutics had a negative net margin of 215.92% and a negative return on equity of 28.01%. The firm had revenue of $7.30 million during the quarter, compared to analyst estimates of $5.83 million. During the same quarter in the prior year, the firm earned ($0.22) EPS. The business’s revenue for the quarter was up 49.0% compared to the same quarter last year. sell-side analysts expect that Intellia Therapeutics will post -1.68 earnings per share for the current fiscal year.

In other news, major shareholder Institutes For Biomed Novartis sold 1,523,000 shares of the stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $18.30, for a total transaction of $27,870,900.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Nessan Bermingham sold 336,783 shares of the stock in a transaction that occurred on Friday, December 8th. The shares were sold at an average price of $20.78, for a total value of $6,998,350.74. Following the transaction, the chief executive officer now owns 696,000 shares of the company’s stock, valued at $14,462,880. The disclosure for this sale can be found here. Insiders have sold a total of 1,971,283 shares of company stock valued at $37,137,161 over the last quarter. Corporate insiders own 12.80% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in Intellia Therapeutics by 10.2% in the second quarter. Vanguard Group Inc. now owns 997,288 shares of the company’s stock worth $15,957,000 after buying an additional 92,580 shares during the last quarter. GMT Capital Corp bought a new stake in Intellia Therapeutics in the third quarter worth $8,214,000. Granahan Investment Management Inc. MA lifted its position in Intellia Therapeutics by 7.0% in the third quarter. Granahan Investment Management Inc. MA now owns 286,144 shares of the company’s stock worth $7,111,000 after buying an additional 18,784 shares during the last quarter. Ark Investment Management LLC lifted its position in Intellia Therapeutics by 118.9% in the second quarter. Ark Investment Management LLC now owns 174,810 shares of the company’s stock worth $2,797,000 after buying an additional 94,960 shares during the last quarter. Finally, State Street Corp lifted its position in Intellia Therapeutics by 52.0% in the second quarter. State Street Corp now owns 164,798 shares of the company’s stock worth $2,638,000 after buying an additional 56,363 shares during the last quarter. Institutional investors own 49.55% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Intellia Therapeutics (NTLA) Given “Hold” Rating at Oppenheimer” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://www.watchlistnews.com/intellia-therapeutics-ntla-given-hold-rating-at-oppenheimer-2/1771464.html.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.